Skp2 inhibitor 3 (E35), a potent antitumor agent, acts as a robust inhibitor of S-phase kinase-associated protein 2 (SKP2) with an IC50 of 4.86 μM for Skp2-Cks1 binding. It significantly suppresses colony formation and migration, while inducing cell cycle arrest in the S-phase.